Abstract 63P
Background
Colorectal cancer is one of the most common cancers in our country. Different clinicopathological features and outcome have been demonstrated between right and left CRC. In our study, we aim to characterize tumor sidedness, clinical profile and histological features of colorectal cancer to improve oncological care.
Methods
The data was retrospectively taken from Medical Oncology OPD Registry, YGH, over one year period from January, 2020 to December, 2020. Summary statistics were used to describe results.
Results
Total 225 (63 right side and 162 left side) patients were included in this study. Right sided tumor included from caecum to splenic flexure. Left sided one represented the remaining large bowel including rectum. The sites observed were caecum (6.6%), ascending colon (9.3%), hepatic flexure (6.6%), transverse colon (3.5%), splenic flexure (1.7%), descending colon (5.7%), sigmoid colon (7.5%), recto-sigmoid (12%) and rectum (46%) respectively. Mean age was 52 years, the youngest was 14 years and the oldest was 89 years. Forty percents of patients were <50 years of age. In right side, male patients (52%) were more than female patients (48%). In left side, slight female preponderance over male (51% Vs 49%) was seen. Presentation with intestinal obstruction or perforation was more commonly seen in right side (38%) than left side (22%). The most common histological subtype in both sides was moderately differentiated adenocarcinoma. Special subtype (mucinous and signet ring cell type) was more commonly seen in right side (24%) than left side (10.5%). More than 80% of patients came with advanced stage (stage III and IV) in both sides. The most common site of metastasis from both sides was peritoneum and liver.
Conclusions
In this study, there were more patients with left-sided CRC than right-sided. And like other countries, the burden of disease in younger patients is quite concerning. As most patients were diagnosed at advanced stage, necessary interventions for CRC awareness should be promoted. This study also highlights that clinicopathological differences exist between right and left colorectal cancer, possibly indicating prognostic significance that might improve the oncological care.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
79P - Outcomes by baseline liver function in patients with unresectable hepatocellular carcinoma treated with tremelimumab and durvalumab in the phase III HIMALAYA study
Presenter: Arndt Vogel
Session: Poster viewing 02
82P - A randomized controlled, open-label, adaptive phase III clinical trial to evaluate safety and efficacy of EndoTAG-1 plus gemcitabine versus gemcitabine alone in patients with measurable locally advanced and/or metastatic adenocarcinoma of the pancreas after FOLFIRINOX
Presenter: Muh-Hwan Su
Session: Poster viewing 02
83P - Impact of viral aetiology in the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC)
Presenter: Stephen Chan
Session: Poster viewing 02
84P - Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: A large real life worldwide population
Presenter: Margherita Rimini
Session: Poster viewing 02
86P - Outcomes by primary tumour location in patients with advanced biliary tract cancer treated with durvalumab or placebo plus gemcitabine and cisplatin in the phase III TOPAZ-1 study
Presenter: Aiwu Ruth He
Session: Poster viewing 02
87P - Socio-demographic disparities in esophageal cancer: A SEER analysis
Presenter: Beas Siromoni
Session: Poster viewing 02
88P - Sintilimab plus anlotinib as second-line therapy for metastatic or recurrent gallbladder carcinoma (GBC): A single-arm, phase II study
Presenter: Qingbao Cheng
Session: Poster viewing 02